

ACADIA PHARMACEUTICALS INC

Form 3

August 26, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â NOMURA

INTERNATIONAL PLC

(Last)

(First)

(Middle)

NOMURA HOUSE,Â 1 ST
MARTIN'S-LE-GRAND

(Street)

LONDON,Â X0Â EC1A 4NP

(City)

(State)

(Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

08/18/2005

3. Issuer Name **and** Ticker or Trading Symbol

ACADIA PHARMACEUTICALS INC [ACAD]

4. Relationship of Reporting
Person(s) to Issuer5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

____ Director ☒ 10% Owner____ Officer ☒ Other

(give title below) (specify below)

Member of 13G Group (1)

6. Individual or Joint/Group
Filing(Check Applicable Line)____ Form filed by One Reporting
Person☒ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)Common Stock, par value \$0.0001 per share
("Common Stock")

2,199,010

I

Notes (1) (2)Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)3. Title and Amount of
Securities Underlying
Derivative Security4. Conversion
or Exercise5. Ownership
Form of6. Nature of Indirect
Beneficial
Ownership

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5) Notes <u>(1)</u> <u>(2)</u>
Warrant to purchase Common Stock	10/17/2005	04/20/2010	Common Stock	549,752	\$ 8.15	I	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
NOMURA INTERNATIONAL PLC NOMURA HOUSE 1 ST MARTIN'S-LE-GRAND LONDON,Â X0Â EC1A 4NP	Â	Â X	Â	Member of 13G Group (1)
Nomura Phase4 Ventures LTD NOMURA HOUSE 1 ST MARTIN'S-LE-GRAND LONDON,Â X0Â EC1A 4NP	Â	Â X	Â	Member of 13G Group (1)
Nomura Phase4 Ventures GP LTD NOMURA HOUSE 1 ST MARTIN'S-LE-GRAND LONDON,Â X0Â EC1A 4NP	Â	Â X	Â	Member of 13G Group (1)
Nomura Phase4 Ventures LP NOMURA HOUSE 1 ST MARTIN'S-LE-GRAND LONDON,Â X0Â EC1A 4NP	Â	Â X	Â	Member of 13G Group (1)

Signatures

See Exhibit 99.1 for signature
information.

08/23/2005

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) See Exhibit 99.1 for the identities of each Reporting Person and for a table of all shares beneficially owned directly or indirectly by each of the Reporting Persons.

(2) Directly owned by Nomura Phase4 Ventures LP.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.